


## SUPPLEMENTARY MATERIAL



**Supplementary Figure 1.** Patient inclusion and exclusion flowchart EVT indicates endovascular treatment; CTA, computed tomography angiography; LVO, large vessel occlusion; ICA, internal carotid artery; ICA, internal carotid artery terminus; M1, M1 segment of the middle cerebral artery; M2, M2 segment of the middle cerebral artery; A1/A2, A1 or A2 segment of the anterior cerebral artery; M3/M4, M3 or M4 segment of the middle cerebral artery; MIP, maximum intensity projection; mm, millimeters

**Supplementary Table 1.** Patient characteristics per cohort

	<b>MR CLEAN Registry (n=1110)</b>	<b>PRESTO (n=646)</b>
<b>Age, median (IQR)</b>	71 (60-80)	73 (62-82)
<b>Sex, male (%)</b>	584 (52.6)	358 (55.4)
<b>NIHSS at baseline, median (IQR)</b>	16 (12-20)	4 (2-9)
<b>ASPECTS, median (IQR)</b>	9 (7-10)	n/a*
<b>Occlusion side, left (%)</b>	586 (52.8)	74 (45.7)†
<b>Occlusion location (%)</b>		
Extracranial ICA (isolated)	n/a	2 (1.2)†
Extracranial ICA (with tandem lesion)	37 (3.3)	3 (1.9)†
Intracranial ICA	19 (1.7)	5 (3.1)†
ICA-T	256 (23.1)	10 (6.2)†
M1	651 (58.6)	60 (37.0)†
M2	147 (13.2)	63 (38.9)†
M3/M4	n/a	2 (1.2)†
A1/A2	n/a	4 (2.5)†
Vertebral artery	n/a	2 (1.2)†
Basilar artery	n/a	6 (3.7)†
P1/P2	n/a	5 (3.1)†
No occlusion	0 (0.0)	484 (74.9)
<b>Slice thickness, mm (%)</b>		
<1	503 (45.3)	453 (70.1)
1-2	304 (27.4)	128 (19.8)
≥2	303 (27.3)	65 (10.1)
<b>Slice overlap (%)</b>		
Yes	821 (74.0)	481 (74.5)
No	289 (26.0)	165 (25.5)
<b>Peak Kilovoltage, kV (%)</b>		
≥120	553 (49.8)	319 (49.4)
<120	557 (50.2)	327 (50.6)
<b>Scan phase (%)</b>		
Early arterial	295 (26.6)	177 (27.4)
Peak arterial	187 (16.8)	316 (48.9)
Equilibrium	296 (26.7)	120 (18.6)
Peak venous	230 (20.7)	28 (4.3)
Late venous	102 (9.2)	5 (0.8)

\*ASPECTS was not assessed in PRESTO

†Numbers between parentheses are percentages of total amount of patients with an occlusion (n=162)

NIHSS indicates National Institutes of Health Stroke Scale; ASPECTS, Alberta Stroke Program Early CT

Score; ICA, internal carotid artery; ICA-T, internal carotid artery terminus; M1, M1 segment of the middle cerebral artery; M2, M2 segment of the middle cerebral artery; mm, millimeters; kV, kilovoltage.

**Supplementary Table 2.** Cross-table with occlusion location indicated by the algorithm (rows) versus reference (columns) in the MR CLEAN Registry

	Intracranial ICA/ICA-T	M1	M2	No LVO	Total
<b>Intracranial ICA/ICA-T</b>	243	5	0	0	248
<b>M1</b>	3	636	4	0	643
<b>M2</b>	0	0	113	0	113
<b>No LVO</b>	8	13	25	0	46
<b>Box in affected hemisphere, but not on vessel</b>	11	14	11	0	36
<b>Box in unaffected hemisphere</b>	11	8	5	0	24
<b>Total</b>	276	676	158	0	1110

ICA indicates internal carotid artery; ICA-T, internal carotid artery terminus; M1, M1 segment of middle cerebral artery; M2, M2 segment of middle cerebral artery; LVO, large vessel occlusion.

**Supplementary Table 3.** Cross-table with occlusion location indicated by the algorithm (rows) versus reference (columns) in PRESTO

	Extracranial ICA	Intracranial ICA/ICA-T	M1	M2	M3/M4	A1/A2	Vertebral artery	Basilar artery	P1/P2	No LVO	Total
<b>Intracranial ICA/ICA-T</b>	1	12	0	0	0	0	0	0	0	4	17
<b>M1</b>	1	0	58	0	0	0	0	0	0	20	79
<b>M2</b>	0	0	0	32	0	1	0	0	0	60	93
<b>No LVO</b>	0	2	0	27	2	3	1	6	4	376	421
<b>Box in affected hemisphere, but not on vessel</b>	0	1	0	3	0	0	0	0	1	0	29
<b>Box in unaffected hemisphere</b>	0	0	3	3	0	0	1	0	0	24†	7
<b>Total</b>	2	15	61	65	2	4	2	6	5	484	646

†Patients without LVO and no affected hemisphere

ICA indicates internal carotid artery; ICA-T, internal carotid artery terminus; M1, M1 segment of middle cerebral artery; M2, M2 segment of middle cerebral artery; LVO, large vessel occlusion.

**Supplementary Table 4.** Diagnostic performance for LVO detection according to imaging quality in pooled cohort (MR CLEAN Registry and PRESTO)

	LVO present/ LVO absent	Sensitivity (95% CI)	Specificity (95% CI)	AUC (95% CI)
<b>Slice thickness, mm</b>				
<1	603/353	86 (83-89)	80 (75-84)	0.83 (0.81-0.86)
1-2	331/101	89 (85-92)	81 (72-88)	0.85 (0.81-0.89)
≥2	317/51	88 (84-91)	55 (40-69)	0.71 (0.64-0.78)
<b>Slice overlap</b>				
Yes	932/370	87 (85-89)	80 (75-84)	0.84 (0.81-0.86)
No	319/135	88 (84-91)	72 (63-79)	0.80 (0.76-0.84)
<b>Peak Kilovoltage, kv</b>				
<120	633/251	87 (84-90)	78 (72-83)	0.82 (0.80-0.85)
≥120	618/254	88 (85-90)	78 (72-83)	0.83 (0.80-0.86)
<b>Scan Phase</b>				
Arterial	589/386	88 (85-90)	77 (72-81)	0.82 (0.80-0.85)
Equilibrium	323/93	90 (86-93)	84 (75-91)	0.87 (0.83-0.91)
Venous	339/26	84 (80-88)	65 (44-83)	0.75 (0.65-0.84)

Sensitivity and specificity are presented as percentages. LVO indicates large vessel occlusion; AUC, area under the curve; mm, millimeters; kV, kilovoltage.

**Supplementary Table 5.** Sensitivity per occlusion according to imaging quality in the MR CLEAN Registry

	ICA/ICA-T		M1		M2	
	N	Sensitivity (95% CI)	N	Sensitivity (95% CI)	N	Sensitivity (95% CI)
<b>Slice thickness, mm</b>						
<1	117	89 (82-94)	303	93 (89-95)	83	78 (68-87)
1-2	78	83 (73-91)	187	96 (92-98)	39	72 (55-85)
≥2	81	89 (80-95)	186	94 (90-97)	36	56 (38-72)
<b>Slice overlap</b>						
Yes	191	87 (82-92)	508	94 (92-96)	122	75 (66-82)
No	85	89 (81-95)	168	93 (89-97)	36	61 (43-77)
<b>peak Kilovoltage, kV</b>						
<120	132	86 (79-92)	344	94 (90-96)	81	74 (63-83)
≥120	144	90 (83-94)	332	95 (92-97)	77	69 (57-79)
<b>Scan phase</b>						
Arterial	108	89 (81-94)	298	96 (93-98)	76	79 (68-87)
Equilibrium	68	91 (82-97)	183	95 (90-97)	45	73 (58-85)
Venous	100	85 (76-91)	195	91 (86-95)	37	54 (37-71)

Sensitivity is presented as percentage. ICA indicates internal carotid artery; ICA-T, internal carotid artery terminus; M1, M1 segment of middle cerebral artery; M2, M2 segment of middle cerebral artery; mm, millimeters; kV, kilovoltage.

## MR CLEAN Registry Investigators

### Executive committee

Diederik W.J. Dippel<sup>1</sup>; Aad van der Lugt<sup>2</sup>; Charles B.L.M. Majolie<sup>3</sup>; Yvo B.W.E.M. Roos<sup>4</sup>; Robert J. van Oostenbrugge<sup>5</sup>; Wim H. van Zwam<sup>6</sup>; Jelis Boiten<sup>14</sup>; Jan Albert Vos<sup>8</sup>

### Study coordinators

Ivo G.H. Jansen<sup>3</sup>; Maxim J.H.L. Mulder<sup>1,2</sup>; Robert-Jan B. Goldhoorn<sup>5,6</sup>; Kars C.J. Compagne<sup>2</sup>; Manon Kappelhof<sup>3</sup>

### Local principal investigator

Wouter J. Schoneville<sup>7</sup>; Jan Albert Vos<sup>8</sup>; Charles B.L.M. Majolie<sup>3</sup>; Jonathan M. Coutinho<sup>4</sup>; Marieke J.H. Wermer<sup>9</sup>; Marianne A.A. van Walderveen<sup>10</sup>; Julie Staals<sup>5</sup>; Wim H. van Zwam<sup>6</sup>; Jeannette Hofmeijer<sup>11</sup>; Jasper M. Martens<sup>12</sup>; Geert J. Lycklama à Nijeholt<sup>13</sup>; Jelis Boiten<sup>14</sup>; Bob Roozenbeek<sup>1</sup>; Bart J. Emmer<sup>2</sup>; Sebastiaan F. de Bruijn<sup>15</sup>; Lukas C. van Dijk<sup>16</sup>; H. Bart van der Worp<sup>17</sup>; Rob H. Lo<sup>18</sup>; Ewoud J. van Dijk<sup>19</sup>; Hieronymus D. Boogaarts<sup>20</sup>; Paul L.M. de Kort<sup>21</sup>; Julia van Tuijl<sup>21</sup>; Jo J.P. Peluso<sup>26</sup>; Jan S.P. van den Berg<sup>22</sup>; Boude Wijn A.A.M. van Hasselt<sup>23</sup>; Leo A.M. Aerden<sup>24</sup>; René J. Dallinga<sup>25</sup>; Maarten Uyttenboogaart<sup>28</sup>; Omid Eshghi<sup>29</sup>; Reinoud P.H. Bokkers<sup>29</sup>; Tobien H.C.M.L. Schreuder<sup>30</sup>; Roel J.J. Heijboer<sup>31</sup>; Koos Keizer<sup>32</sup>; Lonneke S.F. Yo<sup>33</sup>; Heleen M. den Hertog<sup>22</sup>; Emiel J.C. Sturm<sup>35</sup>

### Imaging assessment committee

Charles B.L.M. Majolie<sup>3</sup>(chair); Wim H. van Zwam<sup>6</sup>; Aad van der Lugt<sup>2</sup>; Geert J. Lycklama à Nijeholt<sup>13</sup>; Marianne A.A. van Walderveen<sup>10</sup>; Marieke E.S. Sprengers<sup>3</sup>; Sjoerd F.M. Jenniskens<sup>27</sup>; René van den Berg<sup>3</sup>; Albert J. Yoo<sup>37</sup>; Ludo F.M. Beenens<sup>3</sup>; Alida A. Postma<sup>6</sup>; Stefan D. Roosendaal<sup>3</sup>; Bas F.W. van der Kallen<sup>13</sup>; Ido R. van den Wijngaard<sup>13</sup>; Adriaan C.G.M. van Es<sup>2</sup>; Bart J. Emmer<sup>2,3</sup>; Jasper M. Martens<sup>12</sup>; Lonneke S.F. Yo<sup>33</sup>; Jan Albert Vos<sup>8</sup>; Joost Bot<sup>36</sup>; Pieter-Jan van Doormaal<sup>2</sup>.

### Writing committee

Diederik W.J. Dippel<sup>1</sup>(chair); Aad van der Lugt<sup>2</sup>; Charles B.L.M. Majolie<sup>3</sup>; Yvo B.W.E.M. Roos<sup>4</sup>; Robert J. van Oostenbrugge<sup>5</sup>; Wim H. van Zwam<sup>6</sup>; Geert J. Lycklama à Nijeholt<sup>13</sup>; Jelis Boiten<sup>14</sup>; Jan Albert Vos<sup>8</sup>; Wouter J. Schoneville<sup>7</sup>; Jeannette Hofmeijer<sup>11</sup>; Jasper M. Martens<sup>12</sup>; H. Bart van der Worp<sup>17</sup>; Rob H. Lo<sup>18</sup>

### Adverse event committee

Robert J. van Oostenbrugge<sup>5</sup>(chair); Jeannette Hofmeijer<sup>11</sup>; H. Zwenneke Flach<sup>23</sup>

### Trial methodologist

Hester F. Lingsma<sup>38</sup>

### Research nurses / local trial coordinators

Naziha el Ghannouti<sup>1</sup>; Martin Sterrenberg<sup>1</sup>; Corina Puppels<sup>7</sup>; Wilma Pellikaan<sup>7</sup>; Rita Sprengers<sup>4</sup>; Marjan Elfrink<sup>11</sup>; Joke de Meris<sup>14</sup>; Tamara Vermeulen<sup>14</sup>; Annet Geerlings<sup>19</sup>; Gina van Vemde<sup>22</sup>; Tiny Simons<sup>30</sup>; Cathelijn van Rijswijk<sup>21</sup>; Gert Messchendorp<sup>28</sup>; Hester Bongenaar<sup>32</sup>; Karin Bodde<sup>24</sup>; Sandra Kleijn<sup>34</sup>; Jasmijn Lodico<sup>34</sup>; Hanneke Droste<sup>34</sup>; M. Wollaert<sup>5</sup>; D. Jeurissen<sup>5</sup>; Ernas Bos<sup>9</sup>; Yvonne Drabbe<sup>15</sup>; Nicoline Aaldering<sup>11</sup>; Berber Zweedijk<sup>17</sup>; Mostafa Khalilzada<sup>15</sup>.

### PhD / Medical students

Esmee Venema<sup>38</sup>; Vicky Chalos<sup>1,38</sup>; Ralph R. Geuskens<sup>3</sup>; Tim van Straaten<sup>19</sup>; Saliha Ergezen<sup>1</sup>; Roger R.M. Harmsma<sup>1</sup>; Daan Muijres<sup>1</sup>; Anouk de Jong<sup>1</sup>; Wouter Hinsenveld<sup>5,6</sup>; Olvert A. Berkhemer<sup>1,3,6</sup>; Anna M.M.

Boers<sup>3,39</sup>; J. Huguet<sup>3</sup>; P.F.C. Groot<sup>3</sup>; Marieke A. Mens<sup>3</sup>; Katinka R. van Kranendonk<sup>3</sup>; Kilian M. Treurniet<sup>3</sup>; Manon L. Tolhuijsen<sup>3</sup>; Heitor Alves<sup>3</sup>.

#### List of affiliations

Department of Neurology<sup>1</sup>, Radiology<sup>2</sup>, Public Health<sup>38</sup>, Erasmus MC University Medical Center;  
Department of Radiology and Nuclear Medicine<sup>3</sup>, Neurology<sup>4</sup>, Biomedical Engineering & Physics<sup>39</sup>, Amsterdam UMC, University of Amsterdam, Amsterdam;  
Department of Neurology<sup>5</sup>, Radiology<sup>6</sup>, Maastricht University Medical Center and Cardiovascular Research Institute Maastricht (CARIM);  
Department of Neurology<sup>7</sup>, Radiology<sup>8</sup>, Sint Antonius Hospital, Nieuwegein;  
Department of Neurology<sup>9</sup>, Radiology<sup>10</sup>, Leiden University Medical Center;  
Department of Neurology<sup>11</sup>, Radiology<sup>12</sup>, Rijnstate Hospital, Arnhem;  
Department of Radiology<sup>13</sup>, Neurology<sup>14</sup>, Haaglanden MC, the Hague;  
Department of Neurology<sup>15</sup>, Radiology<sup>16</sup>, HAGA Hospital, the Hague;  
Department of Neurology<sup>17</sup>, Radiology<sup>18</sup>, University Medical Center Utrecht;  
Department of Neurology<sup>19</sup>, Neurosurgery<sup>20</sup>, Radiology<sup>27</sup>, Radboud University Medical Center, Nijmegen;  
Department of Neurology<sup>21</sup>, Radiology<sup>26</sup>, Elisabeth-Tweesteden ziekenhuis, Tilburg;  
Department of Neurology<sup>22</sup>, Radiology<sup>23</sup>, Isala Klinieken, Zwolle;  
Department of Neurology<sup>24</sup>, Radiology<sup>25</sup>, Reinier de Graaf Gasthuis, Delft;  
Department of Neurology<sup>28</sup>, Radiology<sup>29</sup>, University Medical Center Groningen;  
Department of Neurology<sup>30</sup>, Radiology<sup>31</sup>, Atrium Medical Center, Heerlen;  
Department of Neurology<sup>32</sup>, Radiology<sup>33</sup>, Catharina Hospital, Eindhoven;  
Department of Neurology<sup>34</sup>, Radiology<sup>35</sup>, Medisch Spectrum Twente, Enschede;  
Department of Radiology<sup>36</sup>, Amsterdam UMC, Vrije Universiteit van Amsterdam, Amsterdam;  
Department of Radiology<sup>37</sup>, Texas Stroke Institute, Texas, United States of America.

## **PRESTO Investigators**

#### Executive committee

Diederik W.J. Dippel<sup>1</sup>; Bob Roozenbeek<sup>1,2</sup>; Henk Kerkhoff<sup>3</sup>; Hester F. Lingsma<sup>4</sup>; Aad van der Lugt<sup>2</sup>; Adriaan C.G.M van Es<sup>5</sup>; Anouk D. Rozeman<sup>3</sup>; Walid Moudrous<sup>6</sup>; Frédérique H. Vermeij<sup>7</sup>

#### Study Coordinators

Esmee Venema<sup>1,4</sup>; Martijne H.C. Duvekot<sup>1,3</sup>

#### Steering committee

Diederik W.J. Dippel<sup>1</sup>; Bob Roozenbeek<sup>1,2</sup>; Hester F. Lingsma<sup>4</sup>; Aad van der Lugt<sup>2</sup>; Adriaan C.G.M. van Es<sup>5</sup>; Henk Kerkhoff<sup>3</sup>; Anouk D. Rozeman<sup>3</sup>; Walid Moudrous<sup>6</sup>; Frédérique H. Vermeij<sup>7</sup>; Kees C.L. Alblas<sup>7</sup>; Laus J.M.M. Mulder<sup>8</sup>; Annemarie D. Wijnhoud<sup>9</sup>; Lisette Maasland<sup>10</sup>; Roeland P.J. van Eijkelenburg<sup>11</sup>; Marileen Biekart<sup>12</sup>; M.L. Willeboer<sup>13</sup>; Bianca Buijck<sup>14</sup>

#### Imaging committee

Bob Roozenbeek<sup>1,2</sup>; Henk Kerkhoff<sup>3</sup>; Aad van der Lugt<sup>2</sup>; Adriaan C.G.M. van Es<sup>5</sup>

**Imaging core laboratory**

Aad van der Lugt<sup>2</sup>; Adriaan C.G.M. van Es<sup>5</sup>; Pieter Jan van Doormaal<sup>2</sup>; Jeannette Bakker<sup>15</sup>; Jan-Hein Hensen<sup>16</sup>, Aarnout Plaisier<sup>17</sup>; Geert Lycklama à Nijeholt<sup>18</sup>

**Local principal investigators**

Diederik W.J. Dippel<sup>1</sup>; Bob Roozenbeek<sup>1,2</sup>; Aad van der Lugt<sup>2</sup>; Amber Hoek<sup>19</sup>; Henk Kerkhoff<sup>3</sup>; Anouk D. Rozeman<sup>3</sup>; Jeannette Bakker<sup>15</sup>; Erick Oskam<sup>20</sup>; Walid Moudrous<sup>6</sup>; Jan-Hein Hensen<sup>16</sup>; Frédérique H. Vermeij<sup>7</sup>; Mandy M.A. van der Zon<sup>21</sup>; Egon D. Zwets<sup>22</sup>; Kees C.L. Alblas<sup>7</sup>; Laus J.M.M. Mulder<sup>8</sup>; Jan Willem Kuiper<sup>23</sup>; Annemarie D. Wijnhoud<sup>9</sup>; Bruno J.M. van Moll<sup>9</sup>; Aarnout Plaisier<sup>17</sup>; Lisette Maasland<sup>10</sup>; Mirjam Woudenberg<sup>24</sup>; Roeland P.J. van Eijkelenburg<sup>11</sup>; Arnoud M. de Leeuw<sup>25</sup>

**Local trial coordinators**

Anja Noordam-Reijm<sup>12</sup>; Timo Bevelander<sup>13</sup>

**PhD / Medical students**

Vicky Chalos<sup>1,2,3</sup>; Eveline J.A. Wiegers<sup>4</sup>; Lennard Wolff<sup>2</sup>; Dennis C. van Kalkeren<sup>1</sup>; Jochem van den Biggelaar<sup>1</sup>

**List of affiliations**

Department of Neurology<sup>1</sup>, Radiology & Nuclear Medicine<sup>2</sup>, Public Health<sup>4</sup>, Emergency Medicine<sup>19</sup>, Erasmus MC University Medical Centre, Rotterdam;  
Department of Neurology<sup>3</sup>, Radiology<sup>15</sup>, Emergency Medicine<sup>20</sup>, Albert Schweitzer hospital, Dordrecht;  
Department of Radiology<sup>5</sup>, Leiden University Medical Center, Leiden;  
Department of Neurology<sup>6</sup>, Radiology<sup>16</sup>, Maasstad hospital, Rotterdam;  
Department of Neurology<sup>7</sup>, Radiology<sup>21</sup>, Emergency Medicine<sup>21</sup>, Franciscus Gasthuis & Vlietland, Rotterdam;  
Department of Neurology<sup>8</sup>, Radiology<sup>23</sup>, Ikazia hospital, Rotterdam;  
Department of Neurology<sup>9</sup>, Radiology<sup>17</sup>, IJsselland hospital, Rotterdam;  
Department of Neurology<sup>10</sup>, Radiology<sup>24</sup>, van Weel Bethesda hospital, Dirksland;  
Department of Neurology<sup>11</sup>, Radiology<sup>25</sup>, Rivas Zorggroep Beatrix hospital, Gorinchem;  
Ambulance service Rotterdam-Rijnmond<sup>12</sup>, Barendrecht;  
Ambulance service Zuid-Holland Zuid<sup>13</sup>, Papendrecht;  
Rotterdam Stroke Service<sup>14</sup>, Rotterdam;  
Department of Radiology<sup>18</sup>, Haaglanden Medical Center, The Hague.